Showing results (1121-1130 of 31,365) with videos related to
Sort By:
Pageof 3,137
Journal of Medicinal Chemistry|June 25, 2004
Synthesis, biological activity, and three-dimensional quantitative structure-activity relationship model for a series of benzo[c]quinolizin-3-ones, nonsteroidal inhibitors of human steroid 5alpha-reductase 1Ernesto G Occhiato, Alessandro Ferrali, Gloria Menchi, et al.Journal of Medicinal Chemistry|June 25, 2004
Synthesis and biological evaluation of 3-heterocyclyl-7,8,9,10-tetrahydro-(7,10-ethano)-1,2,4-triazolo[3,4-a]phthalazines and analogues as subtype-selective inverse agonists for the GABA(A)alpha5 benzodiazepine binding siteLeslie J Street, Francine Sternfeld, Richard A Jelley, et al.Journal of Medicinal Chemistry|August 6, 2004
A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cellsPeter S Galatin, Donald J AbrahamJournal of Medicinal Chemistry|August 6, 2004
Human integrin alphavbeta5: homology modeling and ligand bindingLuciana Marinelli, Kay-E Gottschalk, Axel Meyer, et al.Journal of Medicinal Chemistry|August 6, 2004
Design, synthesis, and biological evaluation of new cyclic disulfide decapeptides that inhibit the binding of AP-1 to DNAKeiichi Tsuchida, Hisaaki Chaki, Tadakazu Takakura, et al.Journal of Medicinal Chemistry|August 6, 2004
Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonistsChi B Vu, Bo Peng, Gnanasambandam Kumaravel, et al.Journal of Medicinal Chemistry|August 6, 2004
Tetramethylcyclopropyl analogue of a leading antiepileptic drug, valproic acid. Synthesis and evaluation of anticonvulsant activity of its amide derivativesEyal Sobol, Meir Bialer, Boris YagenJournal of Medicinal Chemistry|March 19, 2004
Validation of molecular docking calculations involving FGF-1 and FGF-2Ian Bytheway, Siska CochranJournal of Medicinal Chemistry|March 19, 2004
Synthesis and biological evaluation of novel chloroethylaminoanthraquinones with potent cytotoxic activity against cisplatin-resistant tumor cellsKlaus Pors, Zennia Paniwnyk, Ketan C Ruparelia, et al.Journal of Medicinal Chemistry|March 5, 2004
Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptorKatherine L Widdowson, John D Elliott, Daniel F Veber, et al.Pageof 3,137